• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Charles River Laboratories International (CRL) Cheap After Its Medigen Vaccine Partnership?

    Simply Wall St·09/01/2026 04:36:42
    Listen to the news

    Charles River Laboratories International (CRL) drew fresh attention after partnering with Medigen Vaccine Biologics on virus seed bank work for a next-generation multivalent enterovirus vaccine, using its biologics testing and Next-Generation Sequencing platforms.

    For investors watching Charles River Laboratories International, the recent collaboration news arrives after a strong run in the share price. The 90 day share price return is 64.91% and the 1 year total shareholder return is 76.50%. This contrasts with a 5 year total shareholder return that is down 35.88%, which suggests momentum has been building more recently than over the longer term.

    Scan beyond Charles River Laboratories International and review a hand picked 39 healthcare AI stocks that are also working at the intersection of advanced diagnostics, data rich platforms, and next generation therapies.

    Bulls point to Charles River Laboratories International’s recent share price surge and fresh collaborations as evidence that the business is resetting. Bears question how much of that is already in the price. The valuation work now has to decide.

    Most Popular Narrative: 8.1% Undervalued

    The most followed narrative values Charles River Laboratories International at $313.61 per share, which sits above the recent close of $288.24. That gap is what the current debate now circles around.

    The acquisition of K.F. (Cambodia) by Charles River Laboratories in January 2026 is more than just another corporate transaction.

    It reflects a deeper reality within the drug development ecosystem.

    Read the complete narrative.

    Want to know why a contract research company earns a premium valuation for buying a primate breeder? The narrative leans heavily on future margins, profit growth, and the price investors may accept for those earnings.

    Result: Fair Value of $313.61 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, investors still need to weigh risks, including any disruption to non human primate supply chains and the fact that Charles River Laboratories International currently reports a net loss.

    Find out about the key risks to this Charles River Laboratories International narrative.

    Next Steps

    Given the mix of optimism around Charles River Laboratories International’s recent moves and concern over its risks, it makes sense to check the underlying data yourself and act promptly. To see the balance of potential upside and downside in one place, review the 2 key rewards and 2 important warning signs.

    Looking for more ideas beyond Charles River Laboratories International?

    If you are serious about building a stronger portfolio, use the Simply Wall Street Screener to compare Charles River Laboratories International with other focused opportunities.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.